Long-term efficacy of sequential vincristine, adriamycin, and dexamethasone (VAD) and bortezomib, thalidomide, and dexamethasone (VTD) as induction chemotherapy followed by high-dose melphalan with autologous stem cell transplantation (auto-SCT) and bortezomib consolidation: a follow-up study of KMM51

High-dose chemotherapy with subsequent autologous stem cell support after primary induction chemotherapy has been considered to be standard in eligible multiple myeloma (MM) patients. In recent years, there has been a great improvement in survival of this subset of patients on the strength of incorporation of novel agents such as bortezomib, thalidomide, and lenalidomide into the induction chemotherapy.